SEC Form 4 · accession 0000899243-19-003263
Apellis Pharmaceuticals, Inc. · APLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nicole D Perry
Officer — Vice President - Finance
Period of report
Feb 8, 2019
Accepted (ET)
Feb 12, 2019 · 4:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492422
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $13.85 | Feb 8, 2019 | A | 22,000 | A | — | Feb 7, 2029 | Common Stock | 22,000 | 22,000 | D |
Explanation of responses
- F1This option was granted on February 8, 2019 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.